Adam M Sonabend1, Arthur S Carminucci1, Benjamin Amendolara1, Mukesh Bansal1, Richard Leung1, Liang Lei1, Ronald Realubit1, Hai Li1, Charles Karan1, Jonathan Yun1, Christopher Showers1, Robert Rothcock1, Jane O1, Andrea Califano1, Peter Canoll1, Jeffrey N Bruce1. 1. Gabriele Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (A.M.S., A.S.C., B.A., R.L., J.Y., C.S., R.R., J.O, P.C., J.N.B.); Department of Systems Biology, Columbia University, New York, New York (M.B., A.C.); Center for Computational Biology and Bioinformatics, Columbia University, New York, New York (M.B., A.C.); Department of Pathology and Cell Biology, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (L.L.); High Throughput Screening Center, Columbia University Medical Center Judith P. Sulzberger Genome Center, New York, New York (R.R., H.L., C.K.); Department of Biochemistry and Molecular Biophysics, Columbia University Medical Center, New York, New York (A.C.); Department of Biomedical Informatics, Columbia University, New York, New York (A.C.); Institute for Cancer Genetics, Columbia University, New York, New York (A.C.); Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York (A.C.).
Abstract
BACKGROUND: Glioblastoma subtypes have been defined based on transcriptional profiling, yet personalized care based on molecular classification remains unexploited. Topoisomerase II (TOP2) contributes to the transcriptional signature of the proneural glioma subtype. Thus, we targeted TOP2 pharmacologically with etoposide in proneural glioma models. METHODS: TOP2 gene expression was evaluated in mouse platelet derived growth factor (PDGF)(+)phosphatase and tensin homolog (PTEN)(-/-)p53(-/-) and PDGF(+)PTEN(-/-) proneural gliomas and cell lines, as well as human glioblastoma from The Cancer Genome Atlas. Correlation between TOP2 transcript levels and etoposide susceptibility was investigated in 139 human cancer cell lines from the Cancer Cell Line Encyclopedia public dataset and in mouse proneural glioma cell lines. Convection-enhanced delivery (CED) of etoposide was tested on cell-based PDGF(+)PTEN(-/-)p53(-/-) and retroviral-based PDGF(+)PTEN(-/-) mouse proneural glioma models. RESULTS: TOP2 expression was significantly higher in human proneural glioblastoma and in mouse proneural tumors at early as well as late stages of development compared with normal brain. TOP2B transcript correlated with susceptibility to etoposide in mouse proneural cell lines and in 139 human cancer cell lines from the Cancer Cell Line Encyclopedia. Intracranial etoposide CED treatment (680 μM) was well tolerated by mice and led to a significant survival benefit in the PDGF(+)PTEN(-/-)p53(-/-) glioma model. Moreover, etoposide CED treatment at 80 μM but not 4 μM led to a significant survival advantage in the PDGF(+)PTEN(-/-) glioma model. CONCLUSIONS: TOP2 is highly expressed in proneural gliomas, rendering its pharmacological targeting by intratumoral administration of etoposide by CED effective on murine proneural gliomas. We provide evidence supporting clinical testing of CED of etoposide with a molecular-based patient selection approach. Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND:Glioblastoma subtypes have been defined based on transcriptional profiling, yet personalized care based on molecular classification remains unexploited. Topoisomerase II (TOP2) contributes to the transcriptional signature of the proneural glioma subtype. Thus, we targeted TOP2 pharmacologically with etoposide in proneural glioma models. METHODS: TOP2 gene expression was evaluated in mouse platelet derived growth factor (PDGF)(+)phosphatase and tensin homolog (PTEN)(-/-)p53(-/-) and PDGF(+)PTEN(-/-) proneural gliomas and cell lines, as well as humanglioblastoma from The Cancer Genome Atlas. Correlation between TOP2 transcript levels and etoposide susceptibility was investigated in 139 humancancer cell lines from the Cancer Cell Line Encyclopedia public dataset and in mouse proneural glioma cell lines. Convection-enhanced delivery (CED) of etoposide was tested on cell-based PDGF(+)PTEN(-/-)p53(-/-) and retroviral-based PDGF(+)PTEN(-/-) mouse proneural glioma models. RESULTS: TOP2 expression was significantly higher in human proneural glioblastoma and in mouse proneural tumors at early as well as late stages of development compared with normal brain. TOP2B transcript correlated with susceptibility to etoposide in mouse proneural cell lines and in 139 humancancer cell lines from the Cancer Cell Line Encyclopedia. Intracranial etoposide CED treatment (680 μM) was well tolerated by mice and led to a significant survival benefit in the PDGF(+)PTEN(-/-)p53(-/-) glioma model. Moreover, etoposide CED treatment at 80 μM but not 4 μM led to a significant survival advantage in the PDGF(+)PTEN(-/-) glioma model. CONCLUSIONS: TOP2 is highly expressed in proneural gliomas, rendering its pharmacological targeting by intratumoral administration of etoposide by CED effective on murine proneural gliomas. We provide evidence supporting clinical testing of CED of etoposide with a molecular-based patient selection approach. Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Adam M Sonabend; R Morgan Stuart; Jonathan Yun; Ted Yanagihara; Hamed Mohajed; Steven Dashnaw; Samuel S Bruce; Truman Brown; Alex Romanov; Manu Sebastian; Fernando Arias-Mendoza; Emilia Bagiella; Peter Canoll; Jeffrey N Bruce Journal: Neuro Oncol Date: 2011-07-12 Impact factor: 12.300
Authors: R H Bobo; D W Laske; A Akbasak; P F Morrison; R L Dedrick; E H Oldfield Journal: Proc Natl Acad Sci U S A Date: 1994-03-15 Impact factor: 11.205
Authors: Jeremy N Rich; Christopher Hans; Beatrix Jones; Edwin S Iversen; Roger E McLendon; B K Ahmed Rasheed; Adrian Dobra; Holly K Dressman; Darell D Bigner; Joseph R Nevins; Mike West Journal: Cancer Res Date: 2005-05-15 Impact factor: 12.701
Authors: Janice M Nigro; Anjan Misra; Li Zhang; Ivan Smirnov; Howard Colman; Chandi Griffin; Natalie Ozburn; Mingang Chen; Edward Pan; Dimpy Koul; W K Alfred Yung; Burt G Feuerstein; Kenneth D Aldape Journal: Cancer Res Date: 2005-03-01 Impact factor: 12.701
Authors: Heidi S Phillips; Samir Kharbanda; Ruihuan Chen; William F Forrest; Robert H Soriano; Thomas D Wu; Anjan Misra; Janice M Nigro; Howard Colman; Liliana Soroceanu; P Mickey Williams; Zora Modrusan; Burt G Feuerstein; Ken Aldape Journal: Cancer Cell Date: 2006-03 Impact factor: 31.743
Authors: D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler Journal: Science Date: 2008-09-04 Impact factor: 47.728
Authors: Tej D Azad; James Pan; Ian D Connolly; Austin Remington; Christy M Wilson; Gerald A Grant Journal: Neurosurg Focus Date: 2015-03 Impact factor: 4.047
Authors: Monica Venere; Craig Horbinski; James F Crish; Xun Jin; Amit Vasanji; Jennifer Major; Amy C Burrows; Cathleen Chang; John Prokop; Quilian Wu; Peter A Sims; Peter Canoll; Matthew K Summers; Steven S Rosenfeld; Jeremy N Rich Journal: Sci Transl Med Date: 2015-09-09 Impact factor: 17.956
Authors: Edgar Gonzalez-Buendia; Junfei Zhao; Lu Wang; Subhas Mukherjee; Daniel Zhang; Víctor A Arrieta; Eric Feldstein; J Robert Kane; Seong Jae Kang; Catalina Lee-Chang; Aayushi Mahajan; Li Chen; Ronald Realubit; Charles Karan; Lisa Magnuson; Craig Horbinski; Stacy A Marshall; Jann N Sarkaria; Ahmed Mohyeldin; Ichiro Nakano; Mukesh Bansal; Charles D James; Daniel J Brat; Atique Ahmed; Peter Canoll; Raul Rabadan; Ali Shilatifard; Adam M Sonabend Journal: Clin Cancer Res Date: 2021-08-25 Impact factor: 12.531
Authors: Hong-Jian Wei; Pavan S Upadhyayula; Antonios N Pouliopoulos; Zachary K Englander; Xu Zhang; Chia-Ing Jan; Jia Guo; Angeliki Mela; Zhiguo Zhang; Tony J C Wang; Jeffrey N Bruce; Peter D Canoll; Neil A Feldstein; Stergios Zacharoulis; Elisa E Konofagou; Cheng-Chia Wu Journal: Int J Radiat Oncol Biol Phys Date: 2020-12-17 Impact factor: 8.013
Authors: Georg Karpel-Massler; Matei A Banu; Chang Shu; Marc-Eric Halatsch; Mike-Andrew Westhoff; Jeffrey N Bruce; Peter Canoll; Markus D Siegelin Journal: Oncotarget Date: 2016-03-15
Authors: Nina P Connolly; Amol C Shetty; Jesse A Stokum; Ina Hoeschele; Marni B Siegel; C Ryan Miller; Anthony J Kim; Cheng-Ying Ho; Eduardo Davila; J Marc Simard; Scott E Devine; John H Rossmeisl; Eric C Holland; Jeffrey A Winkles; Graeme F Woodworth Journal: Sci Rep Date: 2018-01-19 Impact factor: 4.379